{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:16:53Z","timestamp":1783153013409,"version":"3.54.6"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":147,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009886","name":"Puglia Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Aging Research &amp; Lifestyle"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.jarlif.2026.100076","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:18:41Z","timestamp":1780618721000},"page":"100076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer\u2019s Disease in Italy: A scenario analysis"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-7063","authenticated-orcid":false,"given":"Maurizio","family":"Giorelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale Di","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Dimatteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jarlif.2026.100076_bib0001","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/alz.12588","article-title":"Alzheimer's disease research progress in the Mediterranean region: the Alzheimer's association international conference satellite symposium","volume":"18","author":"Sexton","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.jarlif.2026.100076_bib0002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.jarlif.2026.100076_bib0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-a\u03b2 protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"18","key":"10.1016\/j.jarlif.2026.100076_bib0004","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jarlif.2026.100076_bib0005","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s10072-025-08143-5","article-title":"Towards a new value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study","volume":"46","author":"Marra","year":"2025","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.jarlif.2026.100076_bib0006","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1007\/s00415-023-11642-0","article-title":"Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline","volume":"270","author":"Filippi","year":"2023","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.jarlif.2026.100076_bib0007","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1007\/s10072-025-08576-y","article-title":"Italian intersocietal recommendations for restructuring the diagnostic- therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer's disease","volume":"46","author":"Benussi","year":"2025","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.jarlif.2026.100076_bib0008","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.jarlif.2026.100076_bib0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Adm Policy Ment Health"},{"key":"10.1016\/j.jarlif.2026.100076_bib0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"issue":"1","key":"10.1016\/j.jarlif.2026.100076_bib0011","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1532-5415.2007.01503.x","article-title":"Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population","volume":"56","author":"Ravaglia","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.jarlif.2026.100076_bib0012","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1177\/13872877251331243","article-title":"Donanemab eligibility in early Alzheimer's disease: a real-world study","volume":"105","author":"Urso","year":"2025","journal-title":"J Alzheimers Dis"},{"issue":"Pt 4","key":"10.1016\/j.jarlif.2026.100076_bib0013","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1469-1809.1999.6340301.x","article-title":"APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele?","volume":"63","author":"Corbo","year":"1999","journal-title":"Ann Hum Genet"},{"issue":"2","key":"10.1016\/j.jarlif.2026.100076_bib0014","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-240594","article-title":"The profile of the Italian centers for cognitive disorders and dementia in the context of new drugs in Alzheimer's disease","volume":"101","author":"Giaquinto","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.jarlif.2026.100076_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12913-024-11019-7","article-title":"Navigating the future ofAlzheimer's care in Ireland - a service model for disease-modifying therapies in small and medium-sized healthcare systems","volume":"24","author":"Leroi","year":"2024","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.jarlif.2026.100076_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100476","article-title":"Preparing for the implementation of anti-amyloid therapies in Europe: assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic","volume":"13","author":"Rosenberg","year":"2026","journal-title":"J Prev Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.jarlif.2026.100076_bib0017","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/10398562251393775","article-title":"Donanemab in Alzheimer's disease: promise, limitations, and implementation challenges in Australia","volume":"34","author":"Dawood","year":"2026","journal-title":"Australas Psychiatry"},{"issue":"1","key":"10.1016\/j.jarlif.2026.100076_bib0018","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"}],"container-title":["The Journal of Aging Research &amp; Lifestyle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2534773X26000182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2534773X26000182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:30:58Z","timestamp":1783150258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2534773X26000182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"alternative-id":["S2534773X26000182"],"URL":"https:\/\/doi.org\/10.1016\/j.jarlif.2026.100076","relation":{},"ISSN":["2534-773X"],"issn-type":[{"value":"2534-773X","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer\u2019s Disease in Italy: A scenario analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Aging Research & Lifestyle","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jarlif.2026.100076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100076"}}